Oncolytics Biotech (ONCY) Interest & Investment Income (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Interest & Investment Income of $14163.0 for Q2 2017, down 60.15% year-over-year from $35537.0 in Q2 2016, and down 60.15% quarter-over-quarter from $35537.0 in Q2 2016.
Oncolytics Biotech (ONCY) Interest & Investment Income (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Interest & Investment Income for 6 consecutive years, with $14163.0 the latest figure, recorded in Q2 2017.
- In Q2 2017, Interest & Investment Income fell 60.15% year-over-year to $14163.0; the TTM figure through Jun 2017 stood at $144075.0 (up 60.33% YoY), while the FY2025 annual figure was $386000.0, down 60.41% from the prior year.
- Interest & Investment Income retreated to $14163.0 in Q2 2017 per ONCY's latest filing, from $35537.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $50253.0 in Q2 2014 and bottomed at $14163.0 in Q2 2017.
- Historically, Interest & Investment Income has averaged $36018.8 across 4 years, with a median of $39829.5 in 2015.
- Annual changes were most pronounced in 2015 — Interest & Investment Income declined 12.2% — and 2017, when it slumped 60.15%.
- Oncolytics Biotech's Interest & Investment Income stood at $50253.0 in 2014, then fell by 12.2% to $44122.0 in 2015, then decreased by 19.46% to $35537.0 in 2016, then sank by 60.15% to $14163.0 in 2017.
- Business Quant data shows ONCY's Interest & Investment Income at $14163.0 in Q2 2017, $35537.0 in Q2 2016, and $44122.0 in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | 37,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2017 | 14,163.00 |
| Jun 30, 2016 | 35,537.00 |
| Jun 30, 2015 | 44,122.00 |
| Jun 30, 2014 | 50,253.00 |
| Dec 31, 2010 | -40,052.00 |
| Sep 30, 2010 | -6.60 Mn |
| Jun 30, 2010 | -6.58 Mn |
| Mar 31, 2010 | -6.57 Mn |
| Dec 31, 2009 | -5,225.00 |
| Sep 30, 2009 | -3,360.00 |
| Jun 30, 2009 | -3,732.00 |
| Mar 31, 2009 | -17,124.00 |